Immunic Investor Relations Material

Immunic Inc. is a clinical-stage biopharmaceutical company, developing a pipeline of selective oral immunology therapies. The company’s lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. Its other programs are IMU-935 for the restoration of the intestinal barrier in patients suffering from diseases such as inflammatory bowel disease; IMU-856 for restoration of the intestinal barrier function in patients suffering from diseases such as inflammatory bowel disease with diarrhea; and an anti-inflammatory intravenous formulation being developed to treat acute kidney injury.